期刊
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
卷 14, 期 2, 页码 176-181出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCO.0b013e3283428df1
关键词
critical illness; glucose; nutrition; propranolol
资金
- SHC [8660, 8490, 8640, 8760, 9145]
- NIH [2T32GM0825611, 1P50GM60338-01, 5RO1GM56687-03, R01-GM56687, R01-HD049471]
- NIDDR [H133A020102, H133A70019]
- NIGMS [U54/GM62119]
- American Surgical Association
Purpose of review The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. Recent findings At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. Summary Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-gamma agonists are under current investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据